

Amendments to the Claims:

Please amend the claims as set forth hereinafter.

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) New chelidonine derivatives having an anti-tumoral effect, selected from the group ~~comprising~~, consisting of chelidoninyl trifluoroacetate, chelidoninyl tri-chloromethyl carbonate, chelidoninyl methyl succinate, chelidoninyl ethyl oxalate, N-(3-trifluoromethylphenyl)chelidoninylurethane, phenylalanine chelidoninyl ester, proline chelidoninyl ester and/or alanine chelidoninyl ester.
2. (Currently Amended) The chelidonine derivatives according to claim 1, ~~characterized in that~~ wherein the anti-tumoral effect is modulation of cell growth, cell differentiation and/or cell division.
3. (Currently Amended) A pharmaceutical agent comprising at least one chelidonine derivative according to claim 1 ~~or 2 and/or a pharmaceutical agent in accordance with any of claims 3 to 5~~, optionally together with a tolerable pharmaceutical carrier, adjuvant and/or vehicle.
4. (Currently Amended) The pharmaceutical agent according to ~~the preceding claim,~~ claim 3, wherein the carriers are ~~selected from the group comprising~~ fillers, diluents, binders, humectants, disintegrants, dissolution retarders, absorption enhancers, wetting agents, adsorbents and/or lubricants.
5. (Currently Amended) The pharmaceutical agent according to ~~any of claims 3 or 4~~ claim 3, ~~characterized in that~~ wherein the carriers are liposomes, siosomes and/or niosomes.
6. (Currently Amended) Method for prophylaxis, therapy, follow-up and aftercare of diseases

*Second Preliminary Amendment  
National Stage of PCT/DE05/01181*

associated with cell growth, cell differentiation and/or cell division comprising administering to an organism in need thereof Use of a chelidonine derivative chosen from the group comprising consisting of chelidonine acetate, chelidoninyl trifluoroacetate, chelidoninyl trichloromethyl carbonate, chelidoninyl methyl succinate, chelidoninyl ethyl oxalate, N-(3-trifluoromethylphenyl)chelidoninylurethane, phenylalanine chelidoninyl ester, proline chelidoninyl ester, and/or alanine chelidoninyl ester and combinations thereof in a prophylaxis, therapy, follow-up and aftercare of diseases associated with cell growth, cell differentiation and/or cell division effective amount in the prophylaxis, therapy, follow-up and aftercare of diseases associated with cell growth, cell differentiation and/or cell division.

7. (Currently Amended) ~~The use according to the preceding claim, characterized in that~~  
the The method of claim 6, wherein one of said diseases is a tumor disease.
8. (Currently Amended) ~~The use according to the preceding claim, characterized in that~~  
The method of claim 6, wherein  
the tumor diseases are selected from the group of neoplastic tumors, inflammatory tumors, and/or abscesses and combinations thereof, effusions and edema.
9. (Currently Amended) ~~The use according to the preceding claim, characterized in that the tumor is~~  
The method of claim 7, wherein the tumor disease comprises  
a solid tumor or a leukemia.
10. (Currently Amended) ~~The use according to the preceding claim, characterized in that~~  
The method of claim 9, wherein  
the solid tumor is a tumor of the urogenital tract and/or gastrointestinal tract.
11. (Currently Amended) ~~The use according to claim 6, characterized in that~~  
~~the tumor~~ The method of claim 7, wherein the tumor disease is a colon carcinoma, stomach carcinoma, pancreas carcinoma, small intestine carcinoma, ovarian

carcinoma, cervical carcinoma, lung carcinoma, prostate carcinoma, mammary carcinoma, renal cell carcinoma, a brain tumor, head-throat tumor, liver carcinoma, and/or a metastase of the above tumors.

12. (Currently Amended) ~~The use according to claim 6,~~  
~~characterized in that~~ The method of claim 9, wherein  
the solid tumor is a mammary, bronchial, colorectal, and/or prostate carcinoma and/or a metastase of the above tumors.
13. (Currently Amended) ~~The use according to claim 6,~~  
~~characterized in that~~ The method of claim 10, wherein  
the tumor of the urogenital tract is a bladder carcinoma and/or a metastase of such tumors.
14. (Currently Amended) ~~The use according to any of claims 6 to 13,~~  
~~characterized in that~~ The method of claim 6, wherein  
said follow-up is monitoring the effectiveness of an anti-tumor treatment.
15. (Currently Amended) ~~The use according to any of the preceding claims,~~  
~~characterized in that~~ Method for prophylaxis, prevention, diagnosis, attenuation, therapy,  
follow-up and/or aftercare of metastasizing, invasion and/or angiogenesis comprising  
administering to an organism in need thereof  
at least one chelidonine derivative according to claim 1 ~~or 2 and/or a pharmaceutical~~  
~~agent according to any of claims 3 to 5 are employed in the~~ in a prophylaxis, prevention,  
diagnosis, attenuation, therapy, follow-up and/or aftercare of metastasizing, invasion  
and/or angiogenesis effective amount.
16. (Currently Amended) ~~The use according to any of the preceding claims,~~  
~~characterized in that~~ method of claim 15, wherein  
said follow-up is monitoring the effectiveness of an anti-tumor treatment.
17. (Currently Amended) ~~The use according to any of the preceding claims,~~

characterized in that

~~at least one chelidonine derivative according to claim 1 or 2 and/or a pharmaceutical agent according to any of claims 3 to 5 are used in a~~ The method of claim 15, wherein said method is part of a combination therapy.

18. (Currently Amended) ~~The use according to the preceding claim, characterized in that~~ The method of claim 17, wherein said combination therapy comprises a chemotherapy, a treatment with cytostatic agents and/or a radiotherapy.
19. (Currently Amended) ~~The use according to the preceding claim, characterized in that~~ The method of claim 17, wherein the combination therapy comprises an adjuvant, biologically specified form of therapy.
20. (Currently Amended) ~~The use according to the preceding claim, characterized in that~~ The method of claim 19, wherein said form of therapy is an immune therapy.
21. (Currently Amended) ~~The use according to any of the preceding claims to increase the~~ The method of claim 6, wherein the method increases sensitivity of tumor cells to cytostatic agents and/or radiation.
22. (Currently Amended) ~~The use according to any of the preceding claims for inhibiting the~~ The method of claim 6, wherein the method inhibits viability, ~~the~~ proliferation rate of cells in order to induce apoptosis and/or cell cycle arrest.
23. (Currently Amended) ~~The use according to any of the preceding claims, characterized in that~~ The method of claim 15, wherein said at least one chelidonine derivative according to claim 1 ~~or 2 and/or a pharmaceutical agent according to any of claims 3 to 5 are~~ is prepared as gel, poudrage, powder, tablet, sustained-release tablet, premix, emulsion, brew-up formulation, drops, concentrate, granulate, syrup, pellet, bolus, capsule, aerosol, spray and/or inhalant and/or inhalant and

applied in this form.

24. (Currently Amended) ~~The use according to the preceding claim, characterized in that~~ The method of claim 15, wherein at least one chelidone derivative according to claim 1 ~~or 2 and/or a pharmaceutical agent according to any of claims 3 to 5 are~~ is present in a preparation at a concentration of from 0.1 to 99.5, preferably from 0.5 to 95.0, and more preferably from 20.0 to 80.0 weight percent.
25. (Currently Amended) ~~The use according to the preceding claim, characterized in that~~ The method of claim 6, wherein the chelidone derivative according to claim 1 is administered orally, subcutaneously, intravenously, intramuscularly, intraperitoneally, ~~and/or topically~~ via injection, vaginally, rectally and/or nasally.
26. (Currently Amended) ~~The use according to any of the preceding claims, characterized in that~~ The method of claim 6, wherein the at least one chelidone derivative according to claim 1 ~~or 2 and/or a pharmaceutical agent according to any of claims 3 to 5 are employed~~ is administered in overall amounts of from 0.05 to 500 mg per kg, preferably from 5 to 100 mg per kg body weight per 24 hours.
27. (Currently Amended) A method for the preparation of the chelidone derivatives according to claim 1 ~~or 2,~~ ~~characterized in that~~ comprising chelidone acetate is obtained by reacting chelidone with pyridine and acetic anhydride to obtain chelidone acetate.
28. (Currently Amended) ~~The method according to the preceding claim, characterized in that~~ A method for the preparation of the chelidone derivatives according to claim 1, wherein

a mixture of chelidonine, pyridine and acetic anhydride is incubated for at least 12 hours at room temperature and this mixture is subsequently poured in ice water, so that a raw product precipitates, and the raw product is extracted with ether.

29. ~~(Currently Amended) The method according to claim 27,~~  
~~characterized in that~~ A method for the preparation of the chelidonine derivatives according to claim 1, wherein  
chelidoninyl trifluoroacetate, chelidoninyl trichloromethyl carbonate, and/or chelidoninyl methyl succinate are obtained by reacting chelidonine with chloroform and the respective acid chloride, the mixture of chelidonine, chloroform and the respective acid chloride being added with pyridine, and the resulting mixture being incubated for at least 4 hours at room temperature.
30. ~~(Currently Amended) The method according to claim 27,~~  
~~characterized in that~~  
~~chelidoinyl ethyl oxalate is obtained by reacting~~ A method for the preparation of the chelidonine derivatives according to claim 1, wherein chelidonine monophosphate is reacted with oxalic ester chloride to obtain chelidoinyl ethyl oxalate.
31. ~~(Currently Amended) The method according to claim 27,~~  
~~characterized in that~~ A method for the preparation of the chelidonine derivatives according to claim 1, wherein  
~~N-(3-trifluoromethylphenyl)chelidoninylurethane is obtained by reacting chelidonine monohydrate~~ is reacted with 3-trifluoromethylphenylisocyanate to obtain N-(3-trifluoromethylphenyl)chelidoninylurethane.
32. ~~(Currently Amended) The method according to claim 27,~~  
~~characterized in that~~  
~~phenylalanine chelidoninyl ester is obtained by reacting~~ A method for the preparation of the chelidonine derivatives according to claim 1, wherein chelidonine monohydrate is reacted with N-(9-fluorenylmethyloxycarbonyl)-L-phenylalanine to obtain phenylalanine chelidoninyl ester.

33. ~~(Currently Amended) The method according to claim 27, characterized in that~~  
proline chelidoninyl ester is obtained by reacting A method for the preparation of the chelidonine derivatives according to claim 1, wherein chelidonine monohydrate is reacted with N-(9-fluorenylmethyloxycarbonyl)-L-proline to obtain proline chelidoninyl.
34. ~~(Currently Amended) The method according to claim 27, characterized in that~~  
alanine chelidoninyl ester is obtained by reacting A method for the preparation of the chelidonine derivatives according to claim 1, wherein chelidonine monohydrate is reacted with N-(9-fluorenylmethyloxycarbonyl)-L-alanine to obtain alanine chelidoninyl ester.
35. ~~(Currently Amended) A method for the treatment of a tumor disease, characterized in that~~  
at least one chelidonine derivative according to claim 1 or 2 and/or a pharmaceutical agent according to any of claims 3 to 5 is contacted with an organism, preferably The method of claim 6, wherein said organism is a human or an animal.
36. (Cancelled)
37. (Currently Amended) A method for the production of a pharmaceutical agent for the treatment of a tumor disease,  
~~Characterized in that wherein~~  
at least one chelidonine derivative according to claim 1 or 2 and/or a pharmaceutical agent according to any of claims 3 to 5 are is employed together with a pharmaceutically tolerable carrier.
38. (Currently Amended) A kit comprising at least one chelidonine derivative according to claim 1 ~~or 2 and/or a pharmaceutical agent according to any of claims 3 to 5~~, optionally together with information for combining the contents of the kit.

39. (Currently Amended) ~~Use of the~~ The kit according to the preceding claim 38, wherein said kit is used for ~~in the~~ prophylaxis or therapy of tumor diseases.